(Q41944133)

14 October 2017

Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity (English)

1 reference

14 October 2017

Andreas Seidl

1

1 reference

14 October 2017

Otmar Hainzl

2

1 reference

14 October 2017

Marleen Richter

3

1 reference

14 October 2017

Robert Fischer

4

1 reference

14 October 2017

Stephan Böhm

5

1 reference

14 October 2017

Britta Deutel

6

1 reference

14 October 2017

Martin Hartinger

7

1 reference

14 October 2017

Jörg Windisch

8

1 reference

14 October 2017

Nicole Casadevall

9

1 reference

14 October 2017

Gerard Michel London

10

1 reference

14 October 2017

Iain Macdougall

11

1 reference

14 October 2017

18 November 2011

1 reference

14 October 2017

Pharmaceutical Research

1 reference

14 October 2017

29

1 reference

14 October 2017

6

1 reference

14 October 2017

1454-1467

1 reference

Strategies for the assessment of protein aggregates in pharmaceutical biotech product development

14 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349029

Precipitation of a monoclonal antibody by soluble tungsten

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349029

Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349029

Immunogenicity of therapeutic proteins. Part 3: impact of manufacturing changes

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349029

Effects of protein aggregates: an immunologic perspective

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349029

Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349029

Factors influencing the immunogenicity of therapeutic proteins

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349029

Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349029

Immune responses to therapeutic proteins in humans--clinical significance, assessment and prediction

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349029

Degradation products of factor VIII which can lead to increased immunogenicity

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349029

The effect of molecular weight and gel preparation on humoral adjuvancy of silicone oils and silicone gels

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349029

Tungsten-induced protein aggregation: solution behavior

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349029

Impact of illegal trade on the quality of epoetin alfa in Thailand.

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349029

Erythropoietin-Associated PRCA: Still an Unsolved Mystery

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349029

Antibody-mediated acquired pure red cell aplasia (PRCA) after treatment with darbepoetin.

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349029

Reactions to Eprex's adverse reactions.

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349029

Antibody-mediated pure red cell aplasia in a dialysis patient receiving darbepoetin alfa as the sole erythropoietic agent.

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349029

Eprex-associated pure red cell aplasia and leachates

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349029

Interaction of polysorbate 80 with erythropoietin: a case study in protein-surfactant interactions.

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349029

The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes.

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349029

Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery.

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349029

Pure red-cell aplasia and epoetin therapy.

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349029

Antibodies against rHuEPO: native and recombinant

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3349029

Antibody Response to Aggregated Human Interferon Alpha2b in Wild-type and Transgenic Immune Tolerant Mice Depends on Type and Level of Aggregation

18 August 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11095-011-0621-4

A Role for Protein Misfolding in Immunogenicity of Biopharmaceuticals

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11095-011-0621-4

The adjuvant effect of silicone-gel on antibody formation in rats

21 January 2018

1 reference

12 December 2020

Meeting report on protein particles and immunogenicity of therapeutic proteins: filling in the gaps in risk evaluation and mitigation

1 reference

12 December 2020

PRCA in a patient treated with epoetin beta

1 reference

12 December 2020

Silicone oil induced aggregation of proteins

1 reference

12 December 2020

Root Cause Analysis of Tungsten-Induced Protein Aggregation in Pre-filled Syringes

1 reference

12 December 2020

Protein isolated from biopharmaceutical formulations cannot be used for comparative studies: Follow-up to "a case study using Epoetin Alfa from Epogen and EPREX"

1 reference

12 December 2020

The immunogenicity of biopharmaceuticals. Lessons learned and consequences for protein drug development

1 reference

12 December 2020

Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-α (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study

1 reference

12 December 2020

Micelle-associated protein in epoetin formulations: aA risk factor for immunogenicity?

1 reference

12 December 2020

Isoaspartyl post-translational modification triggers autoimmune responses to self-proteins

1 reference

12 December 2020

10.1007/S11095-011-0621-4

Identifiers

DOI

1 reference

14 October 2017

1 reference

14 October 2017

PubMed publication ID

22094831

1 reference